Names and pronunciation
(daw-noe-roo′bi-sin/sye-tare′a- been) Vyxeos
PDF page 357
Loading InternPractice…
Drug reference
(daw-noe-roo′bi-sin/sye-tare′a- been) Vyxeos
PDF page 357
Func. class.: Antineoplastic
PDF page 357
USES: For the treatment of newly diag- nosed therapy-related AML or AML with myelodysplasia-related changes
PDF page 357
DOSAGE AND ROUTES • Adult: IV First induction, 44 mg/m2 daunorubicin liposomal and 100 mg/m2 cytarabine liposomal over 90 min on days 1, 3, and 5; patients who do not achieve a response may receive a second induc- tion. Second induction (given 2-5 wk after first induction cycle), 44 mg/m2 dau- norubicin liposomal and 100 mg/m2 cyta- rabine liposomal on days 1 and 3. Con- solidation therapy (given 5-8 wk after start of the last induction), 29 mg/m2 dau- norubicin liposomal and 65 mg/m2 cytarabine liposomal on days 1 and 3. Patients without disease progression or unacceptable toxicity should receive a sec- ond cycle of consolidation therapy given 5-8 wk after the start of the previous con- solidation
PDF page 357
Available forms: Injection (lyophilized cake) 44 mg daunorubicin/100 mg D cytarbine (single-dose vial)
PDF page 357
• Adult: IV First induction, 44 mg/m2 daunorubicin liposomal and 100 mg/m2 cytarabine liposomal over 90 min on days 1, 3, and 5; patients who do not achieve a response may receive a second induc- tion. Second induction (given 2-5 wk after first induction cycle), 44 mg/m2 dau- norubicin liposomal and 100 mg/m2 cyta- rabine liposomal on days 1 and 3. Con- solidation therapy (given 5-8 wk after start of the last induction), 29 mg/m2 dau- norubicin liposomal and 65 mg/m2 cytarabine liposomal on days 1 and 3. Patients without disease progression or unacceptable toxicity should receive a sec- ond cycle of consolidation therapy given 5-8 wk after the start of the previous con- solidation
PDF page 357